89bio Inc

Company Profile

89bio Inc had its IPO on 2019-11-11 under the ticker symbol ETNB.

The company operates in the Healthcare sector and Biotechnology industry. 89bio Inc has a staff strength of 45 employees.

Stock update

Shares of 89bio Inc opened at $16.57 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $16.57 - $17.48, and closed at $17.13.

This is a +2.57% increase from the previous day's closing price.

A total volume of 594,700 shares were traded at the close of the day’s session.

In the last one week, shares of 89bio Inc have slipped by -3.66%.

89bio Inc's Key Ratios

89bio Inc has a market cap of $1.46 billion, indicating a price to book ratio of 3.1111 and a price to sales ratio of 0.

In the last 12-months 89bio Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-105604000. The EBITDA ratio measures 89bio Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, 89bio Inc’s operating margin was 0% while its return on assets stood at -20.96% with a return of equity of -38.39%.

In Q1, 89bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

89bio Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into 89bio Inc’s profitability.

89bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.9242. Its price to sales ratio in the trailing 12-months stood at 0.

89bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$494.32 million

Total Liabilities

$24.02 million

Operating Cash Flow

$4.11 million

Capital Expenditure

$0

Dividend Payout Ratio

0%

89bio Inc ended 2025 with $494.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $494.32 million while shareholder equity stood at $445.83 million.

89bio Inc ended 2025 with $0 in deferred long-term liabilities, $24.02 million in other current liabilities, 73000.00 in common stock, $-344079000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $350.93 million and cash and short-term investments were $480.88 million. The company’s total short-term debt was $171,000 while long-term debt stood at $24.33 million.

89bio Inc’s total current assets stands at $493.63 million while long-term investments were $0 and short-term investments were $129.95 million. Its net receivables were $0 compared to accounts payable of $16.73 million and inventory worth $0.

In 2025, 89bio Inc's operating cash flow was $4.11 million while its capital expenditure stood at $0.

Comparatively, 89bio Inc paid $0 in dividends in 2025.

Other key metrics

Current Trading Price

$17.13

52-Week High

$20.85

52-Week Low

$2.91

Analyst Target Price

$35.13

89bio Inc stock is currently trading at $17.13 per share. It touched a 52-week high of $20.85 and a 52-week low of $20.85. Analysts tracking the stock have a 12-month average target price of $35.13.

Its 50-day moving average was $16.96 and 200-day moving average was $14.98 The short ratio stood at 5.85 indicating a short percent outstanding of 0%.

Around 63.6% of the company’s stock are held by insiders while 6878.4% are held by institutions.